Characterization of a peripheral neuropathy model induced by the chemotherapeutic agent sorafenib in mice

Sorafenib is a mutikinase inhibitor that modulates cellular pathways related to tumor growth and angiogenesis. It is a first-line treatment option for advanced hepatocellular carcinoma, as well as renal cell carcinoma and metastatic thyroid carcinoma. Several adverse effects are associated with sorafenib, the main one being hand-foot skin reaction (HFSR). HFSR manifests as a sensory hypersensitivity syndrome, primarily affecting peripheral areas, causing symptoms like burning sensation, pain and hyper-keratosis. Severe HFSR frequently causes treatment interruption or dosage reduction, as there are no available options for its clinical management.